C5 and myasthenia gravis: For example, ecuzumab, a monoclonal antibody that inhibits the activation of terminal complement by binding to C5, has been approved for the treatment of Myasthenia gravis (MG) [55] and multifocal motor nerve neuropathy (MMN) [56].